Edwards Lifesciences EVP Larry Wood to resign; Daniel Lippis to lead TAVR business

Edwards Lifesciences Corp

Larry Wood, Corporate VP and Group President of TAVR and Surgical Structural Heart, resigns effective Sept 1, 2025.
Wood departs to accept a senior leadership role at another company outside cardiovascular.
Daniel J. Lippis, current Corporate VP for Japan, Greater China, and Asia Pacific, will succeed as Corporate VP for TAVR.
The transition is effective September 1, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.